Ankyra Therapeutics is a biotech developing anchored immunotherapies aimed at enhancing the therapeutic window of ...

A novel machine learning model enhances colorectal cancer (CRC) prognosis and immunotherapy response prediction by ...

During a live event, Samuel M. Rubinstein, MD, discussed the efficacy and safety outcomes from the KarMMa-3 trial.

A patient with relapsed follicular lymphoma achieved complete remission one month after PMB-CT01 treatment in the phase 1 PMB ...

MHRA approves Loba Biotech to manufacture Pegasys API, enabling pharma& to strengthen UK supply and ensure continued access for eligible patients.

Merck Presents Positive Phase 2 Data for Enpatoran Demonstrating Reduction in Disease Activity in Patients with Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE) with Active L ...

WILLOW is a global, multicenter, randomized, placebo-controlled Phase 2 study evaluating three doses of enpatoran taken twice daily (25 mg, 50 mg and 100 mg) versus placebo plus standard of care (SoC) ...

Lipocine Inc. , a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced that its development candidate LPCN ...

Absolute Risk Reduction (ARR): the absolute difference in the percentage of patients who did not develop grade 4 neutropenia in the test group versus the control group.

Cohort analyses from the WILLOW study reveal clear proof of concept in patients with CLE and SLE with active lupus rash, showing clinically meaningful ...

Detailed price information for Monte Rosa Therapeutics Inc (GLUE-Q) from The Globe and Mail including charting and trades.